Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 11/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.33 |
| ▸ | PRMT7 | Q9NVM4 | 1/20 | 0.33 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9109089 | 0.89 | DOT1L (0.39) | DOT1LPRMT5CCRL2ADORA3USP2 | |
| SCHEMBL9110014 | 0.89 | DOT1L (0.39) | DOT1LPRMT5CCRL2ADORA3USP2 | |
| SCHEMBL9288530 | 0.88 | DOT1L (0.42) | DOT1LPRMT5PRMT7ADORA3USP2 | |
| SCHEMBL9104905 | 0.86 | DOT1L (0.40) | DOT1LPRMT5CCRL2USP2ALDH1A1 | |
| SCHEMBL9104911 | 0.86 | DOT1L (0.40) | DOT1LPRMT5CCRL2USP2ALDH1A1 | |
| SCHEMBL9104458 | 0.85 | DOT1L (0.34) | DOT1LCCRL2USP2ALDH1A1LMNA | |
| SCHEMBL9106660 | 0.84 | DOT1L (0.35) | DOT1LCCRL2ADORA3USP2ALDH1A1 | |
| SCHEMBL9109830 | 0.84 | DOT1L (0.34) | DOT1LPRMT5CCRL2USP2ALDH1A1 | |
| SCHEMBL9109937 | 0.84 | DOT1L (0.34) | DOT1LCCRL2USP2ALDH1A1LMNA | |
| SCHEMBL9104375 | 0.84 | DOT1L (0.39) | DOT1LCCRL2USP2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210252035-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | Epizyme, Inc. | 2021-08-19 | — | — | US | disclosed |
| US-20180280422-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | Epizyme, Inc. | 2018-10-04 | — | — | US | disclosed |
| EP-2646444-B1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS AS MODULATORS OF EPIGENETIC ENZYMES | EPIZYME INC (US) | 2016-03-16 | — | — | EP | disclosed |
| US-20150366893-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | Epizyme, Inc. (US) | 2015-12-24 | — | — | US | disclosed |
| US-9096634-B2 | Substituted purine and 7-deazapurine compounds | Epizyme, Inc. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140051654-A1 | Substituted Purine and 7-Deazapurine Compounds | Epizyme, Inc. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8580762-B2 | Substituted purine and 7-deazapurine compounds | Epizyme, Inc. (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2646444-A1 | SUBSTITUTED PURINE AND 7 - DEAZAPURINE COMPOUNDS AS MODULATORS OF EPIGENETIC ENZYMES | Epizyme, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012075381-A1 | SUBSTITUTED PURINE AND 7 - DEAZAPURINE COMPOUNDS AS MODULATORS OF EPIGENETIC ENZYMES | Epizyme, Inc. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | Epizyme, Inc. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280422-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | TPMT, DIMT1, DAZAP1 | DOT1L 6/4885PRMT5 37/4885PRMT7 65/4885 |
| US-20210252035-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | TPMT, DIMT1, DAZAP1 | DOT1L 6/4885PRMT5 37/4885PRMT7 65/4885 |
| US-20150366893-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | TPMT, DIMT1, DAZAP1 | DOT1L 6/4885PRMT5 37/4885PRMT7 65/4885 |
| US-20140051654-A1 | Substituted Purine and 7-Deazapurine Compounds | TPMT, DIMT1, DAZAP1 | DOT1L 6/4885PRMT5 37/4885PRMT7 65/4885 |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | TPMT, DIMT1, DAZAP1 | DOT1L 6/4885PRMT5 37/4885PRMT7 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.